Assessing DNA integrity is a crucial step to characterize the quality of biological samples prior to in-depth genomic analysis, especially applicable in reproductive medicine, prenatal diagnosis and cancer research. Although many methods have been proposed for the assessment of DNA integrity (by electrophoresis, quantitative PCR and, more recently, microfluidic-based procedures), there is still a need to apply more sensitive and precise methods. The invention relates to a method for determining the level of integrity of DNA molecules in a sample containing DNA by multiplexing Digital PCR, which involves amplifying DNA fragments from the sample with amplification primers designed to produce different and predetermined sizes of overlapping amplicons of the same DNA target region, and oligonucleotide probes which can produce detectable and differential signals upon hybridization. Proof of concepts in two main applications have been carried out to date on human clinical samples (small cohort studies):
- By evaluating the ability of the developed clinical trial to discriminate plasma DNA samples from healthy subjects (n=25) and cancer patients (colorectal cancer (n=23), gastric cancer (n=22), pancreatic cancer (n=11))
- By evaluating the quality of DNA after storage in different blood collection tubes
Patented (priority : 11.2020)
DNA Quality Index - DNA Integrity Method - Multiplexed Digital PCR - Liquid Biopsy - Cancer Diagnosis
Erganeo se tient à votre écoute.